首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1538521

新抗原癌症疫苗市場報告：2030 年趨勢、預測與競爭分析

Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2024年07月01日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

新抗原癌症疫苗的趨勢和預測

預計到 2030 年，全球新抗原癌症疫苗市場預計將達到 9,030 萬美元，2024 年至 2030 年複合年成長率為 22.4%。這個市場的主要驅動力是擴大使用個人化醫療對患者進行個人化治療、全球癌症發病率上升以及免疫療法和個人化醫療的持續進步。全球新抗原癌症疫苗市場前景廣闊，黑色素瘤、腦腫瘤、胃腸道和肺部市場都有機會。

新抗原癌症疫苗細分市場

該研究包括按產品、給藥途徑、細胞、應用和區域對全球新抗原癌症疫苗的預測。

新抗原癌症疫苗市場洞察

Lucintel 預測，個人化新抗原將在預測期內實現高速成長。

在該市場中，肺臟預計在預測期內將呈現最高成長。

預計北美在預測期內將出現最高成長。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球新抗原癌症疫苗市場預計將達到 9,030 萬美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球新抗原癌症疫苗市場預計將以22.4%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 這個市場的主要驅動力是擴大使用個人化醫療來對患者進行個人化治療、全球癌症發病率上升以及免疫療法和個人化醫療的不斷進步。

Q4.市場的主要細分市場是：

A4. 新抗原癌症疫苗市場前景廣闊，在黑色素瘤、腦瘤、胃腸道和肺部市場都有機會。

Q5.市場的主要企業是：

A5. 生產新抗原癌症疫苗的主要企業如下：

Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測個人化新抗原將在預測期內呈現高速成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 預計北美地區在預測期內將出現最高成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球新抗原癌症疫苗市場趨勢（2018-2023）與預測（2024-2030）
全球新抗原癌症疫苗市場（按產品）
- 個人化新抗原疫苗
- 現成的新抗原疫苗
按給藥途徑的全球新抗原癌症疫苗市場
- 靜脈
- 肌肉注射
- 經皮的
- 其他
全球新抗原癌症疫苗市場（按細胞）
- 自體移植
- 同種異體的
全球新抗原癌症疫苗市場（按應用）
- 惡性黑色素瘤
- 腦腫瘤
- 胃腸道
- 肺
- 其他

第4章 2018-2030年區域市場趨勢及預測分析

全球新抗原癌症疫苗市場區域分佈
北美新抗原癌症疫苗市場
歐洲新抗原癌症疫苗市場
亞太地區新抗原癌症疫苗市場
其他地區新抗原癌症疫苗市場

第5章競爭分析

產品系列分析
業務整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 全球新抗原癌症疫苗市場成長機會（按產品）
- 按途徑的全球新抗原癌症疫苗市場成長機會
- 全球新抗原癌症疫苗市場成長機會（按細胞）
- 全球新抗原癌症疫苗市場成長機會（按應用）
- 全球新抗原癌症疫苗市場成長機會（按地區）
全球新抗原癌症疫苗市場新趨勢
戰略分析
- 新產品開發
- 擴大全球新抗原癌症疫苗市場產能
- 全球新抗原癌症疫苗市場的合併、收購與合資
- 認證和許可

第7章主要企業概況

Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody

簡介目錄

Neoantigen Cancer Vaccine Trends and Forecast

The future of the global neoantigen cancer vaccine market looks promising with opportunities in the melanoma, brain cancer, gastrointestinal, and lung markets. The global neoantigen cancer vaccine market is expected to reach an estimated $90.3 million by 2030 with a CAGR of 22.4% from 2024 to 2030. The major drivers for this market are growing use of personalized medicine for customized patient care, rising incidence of cancer globally, and ongoing advancements in immunotherapy and personalized medicine.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Neoantigen Cancer Vaccine by Segment

The study includes a forecast for the global neoantigen cancer vaccine by product, route of administration, cell, application, and region.

Neoantigen Cancer Vaccine Market by Product [Shipment Analysis by Value from 2018 to 2030]:

Personalized Neo-Antigen Vaccine
Off-The Shell Neoantigen Vaccine

Neoantigen Cancer Vaccine Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

Intravenous
Intramuscular
Transdermal
Others

Neoantigen Cancer Vaccine Market by Cell [Shipment Analysis by Value from 2018 to 2030]:

Autologous
Allogenic

Neoantigen Cancer Vaccine Market by Application [Shipment Analysis by Value from 2018 to 2030]:

Melanoma
Brain Cancer
Gastrointestinal
Lung
Others

Neoantigen Cancer Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Neoantigen Cancer Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neoantigen cancer vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neoantigen cancer vaccine companies profiled in this report include-

Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody

Neoantigen Cancer Vaccine Market Insights

Lucintel forecasts that personalized neo-antigen is expected to witness higher growth over the forecast period.

Within this market, lung is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Neoantigen Cancer Vaccine Market

Market Size Estimates: Neoantigen cancer vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neoantigen cancer vaccine market size by various segments, such as by product, route of administration, cell, application, and region in terms of value ($M).

Regional Analysis: Neoantigen cancer vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, route of administrations, cells, applications, and regions for the neoantigen cancer vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neoantigen cancer vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the neoantigen cancer vaccine market size?

Answer: The global neoantigen cancer vaccine market is expected to reach an estimated $90.3 million by 2030.

Q2. What is the growth forecast for neoantigen cancer vaccine market?

Answer: The global neoantigen cancer vaccine market is expected to grow with a CAGR of 22.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the neoantigen cancer vaccine market?

Answer: The major drivers for this market are growing use of personalized medicine for customized patient care, rising incidence of cancer globally, and ongoing advancements in immunotherapy and personalized medicine.

Q4. What are the major segments for neoantigen cancer vaccine market?

Answer: The future of the neoantigen cancer vaccine market looks promising with opportunities in the melanoma, brain cancer, gastrointestinal, and lung markets.

Q5. Who are the key neoantigen cancer vaccine market companies?

Answer: Some of the key neoantigen cancer vaccine companies are as follows:

Avidea Technologies
Agenus
Roche
Nouscom
Genocea Biosciences
Gritstone Oncology
Gilead Sciences
BioNTech
ISA Pharmaceutical
Vaccibody

Q6. Which neoantigen cancer vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that personalized neo-antigen is expected to witness higher growth over the forecast period.

Q7. In neoantigen cancer vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the neoantigen cancer vaccine market by product (personalized neo-antigen vaccine and off-the shell neoantigen vaccine), route of administration (intravenous, intramuscular, transdermal, and others), cell (autologous and allogenic), application (melanoma, brain cancer, gastrointestinal, lung, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Neoantigen Cancer Vaccine Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Neoantigen Cancer Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Neoantigen Cancer Vaccine Market by Product
- 3.3.1: Personalized Neo-Antigen Vaccine
- 3.3.2: Off-The Shell Neoantigen Vaccine
3.4: Global Neoantigen Cancer Vaccine Market by Route of Administration
- 3.4.1: Intravenous
- 3.4.2: Intramuscular
- 3.4.3: Transdermal
- 3.4.4: Others
3.5: Global Neoantigen Cancer Vaccine Market by Cell
- 3.5.1: Autologous
- 3.5.2: Allogenic
3.6: Global Neoantigen Cancer Vaccine Market by Application
- 3.6.1: Melanoma
- 3.6.2: Brain cancer
- 3.6.3: Gastrointestinal
- 3.6.4: Lung
- 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Neoantigen Cancer Vaccine Market by Region
4.2: North American Neoantigen Cancer Vaccine Market
- 4.2.1: North American Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
- 4.2.2: North American Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
4.3: European Neoantigen Cancer Vaccine Market
- 4.3.1: European Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
- 4.3.2: European Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
4.4: APAC Neoantigen Cancer Vaccine Market
- 4.4.1: APAC Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
- 4.4.2: APAC Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
4.5: ROW Neoantigen Cancer Vaccine Market
- 4.5.1: ROW Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
- 4.5.2: ROW Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Product
- 6.1.2: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Route of Administration
- 6.1.3: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Cell
- 6.1.4: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Application
- 6.1.5: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Region
6.2: Emerging Trends in the Global Neoantigen Cancer Vaccine Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Neoantigen Cancer Vaccine Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neoantigen Cancer Vaccine Market
- 6.3.4: Certification and Licensing